Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.

Ehab BakbakAishwarya KrishnarajDeepak L BhattAdrian QuanBrady ParkAsaad I BakbakBasel BariKristin A TerenziYi PanElizabeth J FryDaniella C TerenziPankaj PuarTayyab S KhanOri D RotsteinC David MazerLawrence A LeiterHwee TeohDavid A HessSubodh Verma

Published in: Med (New York, N.Y.) (2024)

HLS Therapeutics provided the IPE in kind and had no role in the study design, conduct, analyses, or interpretation.

Keyphrases

cell therapy
stem cells
single cell
mesenchymal stem cells
study protocol
clinical trial
phase iii
phase ii
ionic liquid
tissue engineering
bone marrow
double blind